10 Best Cancer Stocks to Invest in for Long-Term Gains

5. TG Therapeutics, Inc. (NASDAQ:TGTX)

Number of Hedge Fund Holders: 36

Total 5-Year Return: 86.96%

TG Therapeutics, Inc. (NASDAQ:TGTX) is a biopharmaceutical company focused on developing and commercializing innovative treatments for B-cell malignancies and autoimmune diseases. Its portfolio includes FDA-approved oral drugs and monoclonal antibodies targeting cancers like chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), follicular lymphoma (FL), and autoimmune conditions such as multiple sclerosis (MS).

H.C. Wainwright analyst Edward White reaffirmed his Buy recommendation on the stock on March 4, citing a price objective of $55. The analyst emphasized that TG Therapeutics, Inc. (NASDAQ:TGTX)’s solid financial results and bright future are the main reasons he maintained the rating. Strong Briumvi sales drove the company’s fourth-quarter 2024 earnings, which exceeded GAAP and non-GAAP EPS projections. Additionally, the company’s revenue increased by 146% year over year to $108.18 million. The positive outlook for 2025, which anticipates significant growth in revenue and earnings, also gives Analyst White hope. With a 26.3% increase so far this year, the company is among the best cancer stocks to invest in for long-term gains.

ClearBridge Small Cap Growth Strategy stated the following regarding TG Therapeutics, Inc. (NASDAQ:TGTX) in its Q4 2024 investor letter:

“2024 proved a particularly active year for new idea generation: we added 23 new investments while exiting 29 due to a variety of considerations, including acquisitions, market capitalization constraints, and our assessment of forward return potential. While many of the new investments we made during the year are of relatively modest size, we will continue to build these positions over time, provided company execution and end market prospects remain intact. In the fourth quarter, we initiated five new investments: Oscar Health, TG Therapeutics, Inc. (NASDAQ:TGTX), Clearwater Analytics, Fluor, and Modine.

TG Therapeutics is a commercial-stage biotechnology company focused on multiple sclerosis (MS), a significant chronic disease end market. Its lead product, Briumvi, has the potential to grow its market share significantly within the largest drug class in the $8 billion MS market.”